Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.00
Bid: 2.01
Ask: 2.06
Change: -0.075 (-3.61%)
Spread: 0.05 (2.488%)
Open: 2.05
High: 2.09
Low: 2.00
Prev. Close: 2.075
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

Mon, 20th Dec 2021 11:41

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 27% at 7.72 pence, 12-month range 4.80p-13.85p. The drug discovery and development company completes GBP3.6 million fundraise via placing and subscription of 32.3 million shares at 11.00 pence each. This is an 80% premium to Friday's closing price of 6.10p. Additionally, ImmuPharma secures a GBP2.2 million subscription from investment firm Lanstead.

----------

Proteome Sciences PLC, up 6.1% to 5.20p, 12-month range 3.07p-10.00p. The drug development services provider wins a new contract in excess of GBP1 million from an unnamed "major pharmaceutical company". Under the terms of the contract, Proteome will analyse large cohorts of clinical samples from a phase 3 clinical trial. Work is expected to start early in the first quarter of 2022

----------

AIM - LOSERS

----------

ThinkSmart Ltd, down 21% at 64.22p, 12-month range 51.00p-115.00p. The Australian digital payments platform reaches an agreement with Afterpay to sell its remaining 10% stake in Clearpay in exchange for 1.7 million shares in Afterpay, worth GBP73.4 million. The disposal will be put to a vote of ThinkSmart shareholders at a meeting on January 14, it adds.

----------

Hurricane Energy PLC, down 14% at 3.60p, 12-month range 0.59p-5.30p. The oil and gas company completes a review into events that led to the rejection of its restructuring plan by the High Court of Justice of England & Wales. The review, overseen by Hurricane's non-executive directors and carried out by an independent solicitor, found that the company's prior board "discharged their fiduciary duties diligently and in good faith". The non-executive directors have agreed following the review that no further action is necessary, and that time and resources should now go towards maximising the future revenue and potential of the company.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
14 Mar 2019 10:41

ImmuPharma Preparing For Lupuzor Drug Managed Access Programme

LONDON (Alliance News) - ImmuPharma PLC said it is in final preparations to open a managed access programme for its lupus drug Lupuzor to patients in Europe.Shares in the drug discovery and

Read more
26 Feb 2019 12:06

ImmuPharma upbeat on product from subsidiary Ureka

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Tuesday that on 25 February, the peer reviewed research journal Nature Communications published a fundamental scientific publication on the proprietary technology 'Urelix' from its subsidiary Ureka.

Read more
31 Dec 2018 12:00

ImmuPharma and Incanthera extend exclusivity period for Nucant agreement

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its clinical development collaboration agreement for its 'Nucant' cancer programme on Monday, with specialist oncology development partner Incanthera.

Read more
7 Dec 2018 11:26

ImmuPharma Progressing To Make Lupuzor Available To Patients

LONDON (Alliance News) - ImmuPharma PLC on Friday said it is currently in the process of making Lupuzor, its drug for the treatment of lupus, available to patients via its managed access drug said

Read more
7 Dec 2018 08:09

Immupharma plots patient recruitment for Lupzor trials

(Sharecast News) - Drug discovery and development outfit Immupharma has progressed its managed access programme on Lupzor as planned, with patient recruitment in France and the UK expected to follow the firm's analysis of regulatory processes across the EU.

Read more
26 Sep 2018 13:55

ImmuPharma still banking on Lupuzor even after failed trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced its interim results for the six months ended 30 June on Wednesday - a period in which its revenue remained negligible at £0.07m, but its drug candidate 'Lupuzor' demonstrated a superior response rate over placebo in its primary analysis on the full set of 202 patients.

Read more
26 Sep 2018 12:53

Wednesday broker round-up

(Sharecast News) - IAG: UBS downgrades to neutral with a target price of 705p.

Read more
26 Sep 2018 12:40

ImmuPharma Interim Loss Widens On Higher Costs And Lower Revenue

LONDON (Alliance News) - ImmuPharma PLC said on Wednesday it continues to progress its lupus treatment Lupuzor, as it saw a widened loss for the first half of 2018 due to higher costs and lower a

Read more
9 Sep 2018 10:59

Sunday share tips: Immupharma, PCF Bank

(Sharecast News) - For the 'Inside the City' column in the Sunday Times, Sabah Meddings wrote a "cautionary tale" about former biotech darling Immupharma, which last year saw its shares rise 227% over a year.

Read more
7 Sep 2018 11:43

ImmuPharma Inks Pact With Incanthera For Nucant Cancer Programme

LONDON (Alliance News) - ImmuPharma PLC said Friday it signed a clinical development collaboration for the Nucant cancer programme with Incanthera Ltd, a specialist oncology development the terms

Read more
7 Sep 2018 08:10

Immupharma to make 'blockbuster' lupus treatment available

(Sharecast News) - Pharmaceutical firm ImmuPharma on Friday signed an agreement for a managed access programme (MAP) for its "ground-breaking" new lupus treatment, Lupuzor.

Read more
14 Jun 2018 12:02

Immupharma Says P140 Peptide Shows Positive Results In CIDP Treatment

LONDON (Alliance News) - ImmuPharma PLC said Thursday that its pre-clinical studies of the P140 peptide showed positive results in the treatment of chronic inflammatory demyelinating were trading

Read more
29 May 2018 09:40

ImmuPharma Excited Despite Widened Loss As Lupuzor Makes Good Results

LONDON (Alliance News) - ImmuPharma PLC said Tuesday it continues to be "excited" by its future potential despite a widened loss for 2017.The drug development company reported a a

Read more
23 Mar 2018 11:17

ImmuPharma Prepares To Report Lupuzor Study Results In April

LONDON (Alliance News) - Drug development company ImmuPharma PLC said on Friday it has been informed by Simbec-Orion that the data-base lock for the Lupuzor pivotal phase III

Read more
25 Jan 2017 14:33

ImmuPharma trial of Lupuzor continuing smoothly

(ShareCast News) - Specialist drug discovery and development company ImmuPharma provided further details of patient participation on Wednesday, following confirmation in December that the company had successfully completed patient recruitment into its pivotal 52-week Phase III clinical trial of Lupu

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.